ZLAB - ザイ・ラボ （Zai Lab Limited）

WANG & LEE GROUP (WLGS) +45%. Marker Therapeutics (MRKR) +37% Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells.LL Flooring Holdings…

Several Chinese stocks rose today after positive sentiment from Wall Street and recent comments made by President Biden.

China''s National Medical Products Administration ((NMPA)) granted priority review to Zai Lab''s (ZLAB) repotrectinib for a type of lung cancer. Read more here

Zai Lab Limited. (NASDAQ:NASDAQ:ZLAB) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ETCompany ParticipantsBilly Cho - Chief Financial OfficerSamantha Du - Founder, Chairperson and…

Zai Lab (NASDAQ: ZLAB ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM. Here''s what investors need to know about the announcement. Earnings Zai Lab beat estimated earnings by 46.32%, reporting an EPS of $-0.51 versus an … Full story available on Benzinga.com

Key Takeaways: New Horizon Health is expected to attract more investors after becoming the seventh Hong Kong biotech stock to shed a designation reserved for high-risk stocks The company’s gross margin has climbed to 84.5% and is expected to remain at 85% to 90% going forward By Molly Wen The China market for early-screening cancer products has grown rapidly in recent years, fueled by the country’s huge cancer caseload and a growing middle class that can afford such services.One major beneficiary of that boom is New Horizon Health Ltd. (6606.HK), whose latest results released last week show its revenue more than tripled to 765 million yuan ($110.8 million) last year. Equally significant, the report also showed the company’s adjusted loss last year narrowed by 59.6% to 100 million yuan. Its improving financial health didn’t end there. The company also said its application to remove the “B” marker from its ticker, which designates high risk stocks, was approved and took effect on March 20.

Karuna Therapeutics (KRTX) announced Monday that its lead asset KarXT co-developed with Zai Lab (ZLAB), reached the main goal in a Phase 3 trial for schizophrenia. Read the full story here.

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001)

The collapse of Silicon Valley Bank has caused panic not just in the U.S. tech industry but also in China, where the bank has been a key player for years among Chinese startups. In recent days, many startups in China have issued statements to reassure their investors that their deposits with SVB will not impact their operations. Before the bank failed and was taken over by U.S. regulators this month, Silicon Valley Bank was the 16th-largest American bank. In foreign markets, SVB’s reputation for financing about half of all U.S. venture-backed technology and health care companies made it a popular choice for companies, including those based in China and backed by U.S. venture capitalists. BeiGene, one of China''s largest biotech companies that specializes in the development of cancer drugs, said that the collapse of SVB would have “no major impact” on its operations, and that its uninsured cash deposits in Silicon Valley Bank totaled only $175 million, or about 3.9% of its cash and other investments.

Zai Lab is set to reach several product milestones this year, as at least eight new products are on track for approval by the end of 2025. Find out more here.

SHANGHAI and CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the company’s partner Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company reported preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRAS G12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the potential tolerability and feasibility of a concurrent combination regimen of a KRAS G12C inhibitor and a PD-1/L1 checkpoint inhibitor.

Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutation Findings will be presented on December 7 at […] The post Zai Lab Partner Mirati Therapeutics Presents Late-Breaking appeared first on Businessfortnight .

The share price of Zai Lab Limited (NASDAQ:ZLAB) rose to $38.56 per share on Wednesday from $33.69. While Zai Lab Limited has overperformed by 14.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZLAB fell by -44.32%, with highs and lows ranging from $74.22 to $20.98, […]

Shares of several Chinese companies are trading higher Tuesday amid hopes that protests in China could spark an easing of COVID restrictions . Here''s a look at some of the names charging higher. Alibaba Group Holding Ltd (NYSE: BABA ) Li Auto Inc (NASDAQ: LI ) Tencent Music Entertainment Group (NYSE: TME ) GDS Holdings Ltd (NASDAQ: GDS ) Lufax Holding Ltd (NYSE: LU ) Zai Lab Ltd (NASDAQ: ZLAB ) KANZHUN Ltd (NASDAQ: BZ ) Futu Holdings … Full story available on Benzinga.com

https://www.investing.com/news/pro/zai-lab-pt-lowered-to-64-at-credit-suisse-432SI-2942822